Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07189403 · ClinicalTrials.gov registry record · Phase 1

A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer

A Phase 1 study of Metastatic Castration-Resistant Prostate Cancer and Advanced or Metastatic Adrenocortical Carcinoma, sponsored by Daiichi Sankyo.

Recruiting
Registry status
Phase 1
Development phase
40
Enrollment target
6
Study locations

NCT07189403 is a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer and Advanced or Metastatic Adrenocortical Carcinoma that is actively recruiting participants, run by Daiichi Sankyo. The registered enrollment target is 40 participants, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (80% lower). The trial reports 6 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07189403, a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer and Advanced or Metastatic Adrenocortical Carcinoma, is actively recruiting participants, sponsored by Daiichi Sankyo.

RECRUITING
Registry status
Phase 1
Development phase
40 participants
Enrollment target
6
Study locations

Study Summary

This FIH study is designed to assess the safety, tolerability, and preliminary efficacy signals of DS9051b in participants with ACC and mCRPC.

Conditions Studied

Metastatic Castration-Resistant Prostate Cancer Advanced or Metastatic Adrenocortical Carcinoma

Interventions

  • DRUG DS9051b

Study Locations (6)

Other

  • Oncopole Claudius Regaud - Toulouse
  • Centre Oscar Lambret - Villejuif
  • Royal Marsden - London

Florida

  • Florida Cancer Specialists - Sarasota

New York

  • Columbia University - New York

Rhode Island

  • Brown University - Providence

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-11-04
Est. Completion 2028-03-01
Phase Phase 1

Sponsor

Daiichi Sankyo

236 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07189403

The ClinicalTrials.gov registry entry for NCT07189403 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (80% lower). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which DS9051b is the first listed.

NCT07189403 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Other, Florida, New York.

Frequently Asked Questions

What is clinical trial NCT07189403 about?

NCT07189403 is a clinical study titled "A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer". This FIH study is designed to assess the safety, tolerability, and preliminary efficacy signals of DS9051b in participants with ACC and mCRPC.

What is the current status of trial NCT07189403?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2025-11-04. Estimated completion is 2028-03-01.

What conditions does trial NCT07189403 study?

This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer, Advanced or Metastatic Adrenocortical Carcinoma.

What interventions are being tested in trial NCT07189403?

The interventions under investigation include: DS9051b (DRUG).

Who is sponsoring clinical trial NCT07189403?

This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07189403 being conducted?

This trial has 6 study locations across Florida, New York, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Castration-Resistant Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Castration-Resistant Prostate Cancer

All registered trials for this condition

Advanced or Metastatic Adrenocortical Carcinoma

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.